New drug combo shows promise in early cancer trial, but expansion halted

NCT ID NCT05162755

Ongoing Disease control Sponsor: Institut de Recherches Internationales Servier Source: ClinicalTrials.gov ↗

First seen Nov 05, 2025 · Last updated Apr 28, 2026 · Updated 25 times

Summary

This early-phase study tested a new drug (S095029) alone and with another drug (Sym021) in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The planned expansion to test triple combinations was canceled for business reasons, not safety concerns.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
Princess Margaret Cancer Centre

Toronto, Canada
START Midwest

Grand Rapids, Michigan, 49546, United States
The START Center for Cancer Care

San Antonio, Texas, 78229, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR